AMEDEO Vaccines

http://www.amedeo.com

29.01.2002

_ Your personal AMEDEO Web page with AVAILABLE ABSTRACTS:

http://amedeo.net/pers.cfm?table=vac&cid=169259

_ Free Medical Journals

http://www.freemedicaljournals.com

________________ ** New articles **  _________________

Centers for Disease Control.

Outbreak of pneumococcal pneumonia among unvaccinated residents of a nursing home--New Jersey, April 2001.

MMWR Morb Mortal Wkly Rep 2001; 50: 707-10.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11787578&aid=B169259&dopt=r&s=vac

Centers for Disease Control.

Progress toward poliomyelitis eradication--South-East Asia, January 2000-June 2001.

MMWR Morb Mortal Wkly Rep 2001; 50: 738-42, 751.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11787582&aid=B169259&dopt=r&s=vac

Centers for Disease Control.

Progress toward poliomyelitis eradication--Eastern Mediterranean Region, January 2000-September 2001.

MMWR Morb Mortal Wkly Rep 2001; 50: 1113-6.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11794622&aid=B169259&dopt=r&s=vac

GUALA A, Garipoli V, Pastore G, Pagani L.

Familial adverse events after measles-mumps-rubella (MMR) vaccination. 

Vaccine 2002; 20: 991.

STUDDERT MJ.

Vaccination of foals and pregnant mares with Duvaxyn EHV1, 4 vaccine.

Vaccine 2002; 20: 992.

GALLO G, Ciofi degli Atti ML, Cerquetti M, Piovesan C, Tozzi AE, Salmaso S.

Impact of a regional Hib vaccination programme in Italy.

Vaccine 2002; 20: 993-5.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803057&aid=B169259&dopt=r&s=vac

PUGACHEV KV, Ocran SW, Guirakhoo F, Furby D, Monath TP.

Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing.

Vaccine 2002; 20: 996-9.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803058&aid=B169259&dopt=r&s=vac

MILSTIEN J, Dellepiane N, Lambert S, Belgharbi L, Rolls C, Knezevic I et al.

Vaccine quality-can a single standard be defined?

Vaccine 2002; 20: 1000-3.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803059&aid=B169259&dopt=r&s=vac

MONATH TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S et al.

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

Vaccine 2002; 20: 1004-18.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803060&aid=B169259&dopt=r&s=vac

LU X, Clements JD, Katz JM.

Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.

Vaccine 2002; 20: 1019-29.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803061&aid=B169259&dopt=r&s=vac

RAGUPATHI G, Cappello S, Yi SS, Canter D, Spassova M, Bornmann WG et al.

Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.

Vaccine 2002; 20: 1030-8.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803062&aid=B169259&dopt=r&s=vac

GILBERT SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R et al.

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.

Vaccine 2002; 20: 1039-45.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803063&aid=B169259&dopt=r&s=vac

HASEGAWA H, Kadowaki S, Watanabe I, Aizawa H, Takahashi H, Iwasaki T et al.

Persistent infection of influenza virus in irradiated mice and its prevention by intranasal vaccination.

Vaccine 2002; 20: 1050-7.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803065&aid=B169259&dopt=r&s=vac

KONISHI E, Fujii A.

Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine.

Vaccine 2002; 20: 1058-67.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803066&aid=B169259&dopt=r&s=vac

SCANLEN M, Paweska JT, Verschoor JA, van Dijk AA.

The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant.

Vaccine 2002; 20: 1079-1088.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803068&aid=B169259&dopt=r&s=vac

TREANOR J, Keitel W, Belshe R, Campbell J, Schiff G, Zangwill K et al.

Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults.

Vaccine 2002; 20: 1099-1105.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803070&aid=B169259&dopt=r&s=vac

DA CUNHA SS, Rodrigues LC, Barreto ML, Dourado I.

Outbreak of aseptic meningitis and mumps after mass vaccination with MMR vaccine using the Leningrad-Zagreb mumps strain.

Vaccine 2002; 20: 1106-12.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803071&aid=B169259&dopt=r&s=vac

BRISSON M, Edmunds WJ.

The cost-effectiveness of varicella vaccination in Canada.

Vaccine 2002; 20: 1113-25.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803072&aid=B169259&dopt=r&s=vac

BUDDLE BM, Wards BJ, Aldwell FE, Collins DM, de Lisle GW.

Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis.

Vaccine 2002; 20: 1126-33.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803073&aid=B169259&dopt=r&s=vac

PEBODY RG, Gay NJ, Hesketh LM, Vyse A, Morgan-Capner P, Brown DW et al.

Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance.

Vaccine 2002; 20: 1134-40.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803074&aid=B169259&dopt=r&s=vac

DUS SANTOS MJ, Wigdorovitz A, Trono K, Rios RD, Franzone PM, Gil F et al.

A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants.

Vaccine 2002; 20: 1141-7.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803075&aid=B169259&dopt=r&s=vac

SETIA S, Mainzer H, Washington ML, Coil G, Snyder R, Weniger BG.

Frequency and causes of vaccine wastage.

Vaccine 2002; 20: 1148-56.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803076&aid=B169259&dopt=r&s=vac

NOTHDURFT HD, Dietrich M, Zuckerman JN, Knobloch J, Kern P, Vollmar J et al.

A new accelerated vaccination schedule for rapid protection against hepatitis A and B.

Vaccine 2002; 20: 1157-62.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803077&aid=B169259&dopt=r&s=vac

SHIAU AL, Liu CW, Wang SY, Tsai CY, Wu CL.

A simple selection system for construction of recombinant gD-negative pseudorabies virus as a vaccine vector.

Vaccine 2002; 20: 1186-95.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803081&aid=B169259&dopt=r&s=vac

KOSTEN TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J et al.

Human therapeutic cocaine vaccine: safety and immunogenicity.

Vaccine 2002; 20: 1196-1204.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803082&aid=B169259&dopt=r&s=vac

HONG W, Xiao S, Zhou R, Fang L, He Q, Wu B et al.

Protection induced by intramuscular immunization with DNA vaccines of pseudorabies in mice, rabbits and piglets.

Vaccine 2002; 20: 1205-14.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803083&aid=B169259&dopt=r&s=vac

NYIKA A, Barbet AF, Burridge MJ, Mahan SM.

DNA vaccination with map1 gene followed by protein boost augments protection against challenge with Cowdria ruminantium, the agent of heartwater.

Vaccine 2002; 20: 1215-25.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803084&aid=B169259&dopt=r&s=vac

GONZALO RM, del Real G, Rodriguez JR, Rodriguez D, Heljasvaara R, Lucas P et al.

A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis.

Vaccine 2002; 20: 1226-31.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803085&aid=B169259&dopt=r&s=vac

GREENBAUM E, Furst A, Kiderman A, Stewart B, Levy R, Schlesinger M et al.

Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine.

Vaccine 2002; 20: 1232-9.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803086&aid=B169259&dopt=r&s=vac

HALPERIN SA, Smith B, Mabrouk T, Germain M, Trepanier P, Hassell T et al.

Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children.

Vaccine 2002; 20: 1240-7.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803087&aid=B169259&dopt=r&s=vac

KIM Y, Nielsen PR, Hodgins D, Chang KO, Saif LJ.

Lactogenic antibody responses in cows vaccinated with recombinant bovine rotavirus-like particles (VLPs) of two serotypes or inactivated bovine rotavirus vaccines.

Vaccine 2002; 20: 1248-1258.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11803088&aid=B169259&dopt=r&s=vac

GOLDBLATT D, Borrow R, Miller E.

Natural and Vaccine-Induced Immunity and Immunologic Memory to Neisseria meningitidis Serogroup C in Young Adults.

J Infect Dis 2002; 185: 397-400.

Abstract: http://www.amedeo.com/lit.cfm?uid=A11807724&aid=B169259&dopt=r&s=vac

_________________________________________________________

http://www.AMEDEO.com

http://www.MedicineonEarth.com

http://www.FreeMedicalJournals.com

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.